SAN FRANCISCO, CA – [Current Date] – Kyverna Therapeutics has announced a significant breakthrough in the treatment of Stiff-Person Syndrome (SPS), a debilitating and rare autoimmune neurological disorder. Its investigational anti-CD19 CAR-T cell therapy, miv-cel (mivocabtagene autoleucel), has demonstrated sustained clinical benefit after one year in the pivotal Phase III KYSA-8 study (NCT06588491). This long-term efficacy and a favorable safety profile position miv-cel to become the first FDA-approved therapeutic specifically for SPS, offering unprecedented hope to patients grappling with this severe condition.
n
The compelling one-year data, which builds upon earlier positive 16-week results, shows a remarkable 49% improvement in the timed 25-Foot Walk (T25FW) test, a key measure of mobility, compared to the 46% improvement observed at week 16. Furthermore, more than one-third of treated patients achieved a T25FW time comparable to healthy adults, completing the walk in less than five seconds. This sustained improvement, alongside a high retention rate of benefit among responders, marks a potential paradigm shift for a disease with no currently approved therapies. Kyverna plans to include this comprehensive one-year data in its rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA).
n
Beyond SPS, Kyverna also revealed promising longer-term data for miv-cel in generalized myasthenia gravis (gMG) from its Phase II/III KYSA-6 study (NCT06193889), further underscoring the broad potential of its CAR-T platform in autoimmune diseases.
n
A Deeper Look: The Main Facts Unveiled
n
Kyverna Therapeutics’ miv-cel has emerged as a beacon of hope for patients suffering from Stiff-Person Syndrome, a condition characterized by progressive muscle stiffness, rigidity, and painful spasms that profoundly impact daily life. The Phase III KYSA-8 trial results indicate not just a transient improvement but a sustained and clinically meaningful one-year benefit, addressing a critical unmet medical need.
n
The core of this exciting development lies in the efficacy demonstrated by miv-cel. Patients in the registrational KYSA-8 study experienced a 49% sustained improvement in the timed 25-Foot Walk (T25FW) at the 12-month mark. This metric, which assesses walking speed and mobility, showed consistent progress from the 46% improvement recorded at the primary analysis point of week 16. The fact that over one-third of patients could complete the T25FW in under five seconds is particularly noteworthy, as this time frame is typically associated with healthy, unaffected adults. For individuals whose mobility is severely compromised by SPS, such an improvement signifies a profound restoration of function and independence. Of those patients who initially achieved a clinically meaningful improvement at the primary analysis, an impressive 95% sustained their benefit through the one-year follow-up, indicating the durability of miv-cel’s effect.
n
Crucially, the safety profile of miv-cel remained well-tolerated throughout the observation period. There were no reported cases of high-grade cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS), two severe adverse events sometimes associated with CAR-T therapies in oncology. Furthermore, no instances of immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) were observed. This favorable safety profile, combined with the robust efficacy, strengthens the therapy’s potential for widespread clinical adoption.
n
This positive one-year data follows Kyverna’s initial announcement at the American Academy of Neurology (AAN) Annual Meeting in April 2026, where the company confirmed that the KYSA-8 study had successfully met both its primary and secondary endpoints after 16 weeks of treatment. The consistency and durability of these results are pivotal for regulatory consideration.
n
A Chronology of Hope: Addressing a Long-Standing Unmet Need
n
Stiff-Person Syndrome, first described in 1956, has historically presented a formidable challenge to the medical community. Characterized by fluctuating muscle rigidity in the trunk and limbs and an increased sensitivity to stimuli such as noise, touch, and emotional distress, SPS can lead to painful spasms and falls, severely impacting quality of life. For decades, treatment options have been largely symptomatic, relying on muscle relaxants, benzodiazepines, and various immunosuppressants, none of which are specifically approved for SPS and often come with significant side effects and limited long-term efficacy.
n
The public awareness of this incredibly rare condition received a significant, albeit unfortunate, boost in December 2022 when world-renowned singer Céline Dion revealed her diagnosis with SPS. Her courageous sharing of her battle brought the struggles of SPS patients into the global spotlight, highlighting the urgent need for effective treatments.
n
In this context of profound unmet need, Kyverna Therapeutics embarked on the development of miv-cel. The KYSA-8 study was initiated as a registrational Phase III trial, meticulously designed to evaluate the safety and efficacy of this novel CAR-T approach. The journey culminated in the initial positive readout at the AAN Annual Meeting in April 2026, where the 16-week data confirmed the therapy’s ability to meet its primary and secondary endpoints.
n
The latest announcement, detailing the sustained one-year benefit, represents a critical milestone. This long-term data provides robust evidence of miv-cel’s enduring impact, a crucial factor for a chronic, progressive condition like SPS. The company’s decision to include these comprehensive one-year results in its rolling Biologics License Application (BLA) submission to the FDA underscores its confidence in miv-cel’s potential for approval and its commitment to bringing this therapy to patients as swiftly as possible. This BLA submission marks the culmination of years of research and development, setting the stage for what could be a landmark approval in rare autoimmune disease treatment.
n
Supporting Data: Unpacking the Clinical Evidence
n
The clinical data from the KYSA-8 study for SPS provides compelling evidence of miv-cel’s efficacy and safety, warranting a closer examination of the metrics and their implications for patients.
n
SPS (KYSA-8) – Detailed Efficacy:nThe primary measure of efficacy, the timed 25-Foot Walk (T25FW), is a standardized clinical assessment used to quantify lower extremity function and mobility. A 49% improvement at 12 months, building upon the 46% at week 16, signifies a substantial and progressive enhancement in a patient’s ability to walk. To put this into perspective, for an individual struggling with severe stiffness and spasms, even a small percentage improvement can translate into a significant gain in functional independence – perhaps the ability to walk unassisted, navigate their home more easily, or participate in activities previously impossible. The fact that more than one-third of patients achieved a T25FW time under 5 seconds, a benchmark for healthy adults, highlights the transformative potential of miv-cel. This is not merely symptomatic relief but a profound functional restoration.
n
The durability of response is equally impressive, with 95% of initial responders maintaining their benefit at one year. This high retention rate is crucial for chronic conditions like SPS, where patients require long-lasting solutions to manage their progressive symptoms and avoid relapse.
n
SPS (KYSA-8) – Safety Profile:nMiv-cel’s safety profile is a key differentiator, particularly given the novelty of CAR-T cell therapies. The absence of high-grade cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) is highly encouraging. CRS is a systemic inflammatory response that can range from mild to life-threatening, while ICANS encompasses a spectrum of neurological toxicities, both of which are commonly observed and managed in CAR-T treatments for oncology indications. The lack of these severe adverse events, along with no cases of immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) – another serious inflammatory condition – suggests a potentially more favorable safety margin for miv-cel when deployed in autoimmune settings, possibly due to differences in target cell biology or disease mechanisms compared to cancer.
n
Mechanism of Action:nMiv-cel is an anti-CD19 CAR-T cell therapy that stimulates CD28. In essence, CAR-T therapy involves genetically engineering a patient’s own T cells (a type of immune cell) to express a chimeric antigen receptor (CAR) that specifically targets an antigen on disease-causing cells. In autoimmune diseases like SPS, a leading hypothesis suggests that autoreactive B cells (which express CD19) play a crucial role in disease pathogenesis by producing autoantibodies or acting as antigen-presenting cells that perpetuate the autoimmune response. By targeting and depleting these CD19-expressing B cells, miv-cel aims to reset the immune system, thereby interrupting the autoimmune attack on the nervous system and leading to sustained clinical improvements. The CD28 co-stimulatory domain enhances T-cell activation and proliferation, contributing to the potency and persistence of the CAR-T cells.
n
Generalized Myasthenia Gravis (gMG) (KYSA-6) – Detailed Efficacy:nThe positive results for miv-cel extend beyond SPS, with promising longer-term data in generalized myasthenia gravis (gMG), another chronic autoimmune neuromuscular disease characterized by fluctuating muscle weakness. From the Phase II portion of the KYSA-6 study, all seven patients achieved clinically meaningful improvements in two key outcome measures at 24 weeks: the Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scales. Mean reductions of 8.3 points in MG-ADL and 11.7 points in QMG were observed.
n
- n
- MG-ADL (Myasthenia Gravis Activities of Daily Living): This patient-reported outcome measures the impact of gMG on daily activities such as talking, chewing, swallowing, breathing, and limb movements. A clinically meaningful improvement on this scale signifies a tangible enhancement in a patient’s ability to perform everyday tasks.
- QMG (Quantitative Myasthenia Gravis): This is a physician-administered scale that objectively assesses the severity of muscle weakness across various muscle groups. Improvements on the QMG scale indicate a reduction in disease severity as observed by clinicians.
n
n
n
These improvements were sustained at the one-year mark for those patients who continued treatment, reinforcing the potential for long-term benefit. Both MG-ADL and QMG are designated as co-primary endpoints for the ongoing Phase III portion of the KYSA-6 study, highlighting their importance in regulatory assessment. The gMG market across the seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) is projected to reach a substantial $13 billion by 2034, growing significantly from its $4.5 billion valuation in 2024. This robust market forecast underscores the commercial significance of miv-cel’s potential entry into the gMG treatment landscape, where current therapies often manage symptoms but do not offer a curative or sustained remission.
n
Official Responses: Voices of Hope and Commitment
The one-year data for miv-cel in SPS has been met with enthusiastic responses from the medical community and the company. Dr. Amanda Piquet, Director of Autoimmune Neurology at the University of Colorado Anschutz School of Medicine, Céline Dion Foundation endowed chair, and lead investigator of the KYSA-8 trial, articulated the profound impact of these findings.
"The results from KYSA-8 are compelling, particularly given the severe burden of SPS and the absence of approved therapies," Dr. Piquet stated. "After a single dose of miv-cel, the sustained improvements observed in mobility, stiffness, and other disease-specific measures, together with a well-tolerated profile, underscore its potential to deliver significant, long-lasting benefit to patients with SPS." Her emphasis on the "severe burden" and "absence of approved therapies" highlights the critical vacuum miv-cel aims to fill. The notion of a "single dose" providing "long-lasting benefit" is particularly appealing, as it contrasts sharply with the chronic, often daily, regimens associated with existing symptomatic treatments.
While no direct quotes from Kyverna’s leadership were provided in the original text regarding this specific one-year data release, it is reasonable to infer their profound satisfaction and strategic intent. A spokesperson from Kyverna Therapeutics would likely reiterate the company’s commitment to advancing innovative therapies for autoimmune diseases. They would probably emphasize that the sustained efficacy and favorable safety profile of miv-cel in SPS represent a critical validation of their CAR-T platform’s potential beyond oncology. The imminent BLA submission signifies a pivotal moment for the company, aligning with its mission to address significant unmet medical needs in rare and debilitating conditions.
Patient advocacy groups, upon reviewing such data, would undoubtedly express immense hope and relief. For years, SPS patients have navigated their condition with limited and often inadequate therapeutic options, facing progressive disability and isolation. The prospect of a therapy that can offer sustained functional improvement and a high degree of safety would be seen as a monumental step forward, potentially transforming the lives of those affected by this rare and cruel disease. Organizations dedicated to supporting SPS patients would likely commend Kyverna’s efforts and advocate for an expedited regulatory review process, recognizing the urgent need for this potential first-in-class treatment.
Implications: A New Era for Autoimmune Disease Treatment
The positive one-year results for miv-cel in SPS and the promising data in gMG carry far-reaching implications across several domains:
For SPS Patients and the Rare Disease Community:
This represents nothing short of a revolution. For decades, SPS patients have faced a bleak prognosis with no disease-modifying treatments. Miv-cel offers the first real hope for sustained remission and significant improvement in quality of life. The ability to regain mobility, reduce painful spasms, and potentially live a more independent life would be transformative. This breakthrough also shines a light on the broader rare disease community, demonstrating that significant investment and innovative science can yield effective therapies for conditions previously deemed untreatable. It fosters optimism that other rare autoimmune diseases might also benefit from similar advanced cellular therapies.
For Kyverna Therapeutics:
The success of miv-cel positions Kyverna as a leader in the emerging field of CAR-T therapies for autoimmune diseases. Achieving a first-to-market advantage in SPS would be a significant commercial and scientific validation. This success would not only establish a strong revenue stream but also provide a powerful proof-of-concept for its CAR-T platform, potentially accelerating the development and adoption of miv-cel for other indications like gMG, and paving the way for future autoimmune targets. This places Kyverna in a strategically enviable position within the biopharmaceutical landscape.
For the CAR-T Therapy Field:
Traditionally confined to oncology, the expansion of CAR-T therapy into autoimmune diseases marks a pivotal moment for the technology itself. It demonstrates the versatility and immense potential of precisely engineered cellular therapies to "reset" dysfunctional immune systems beyond cancer. This could ignite a wave of research and development into CAR-T for a wider array of autoimmune conditions, from lupus and multiple sclerosis to inflammatory bowel diseases, fundamentally changing the therapeutic landscape for these chronic illnesses.
For the Broader Pharmaceutical Industry:
Kyverna’s success could inspire other pharmaceutical companies to invest more heavily in cellular and gene therapies for autoimmune conditions. It highlights the potential for high-value therapies in niche markets, particularly those with significant unmet needs. This could lead to increased competition, innovation, and ultimately, more options for patients.
The Competitive Landscape:
While miv-cel is poised to be the first FDA-approved drug specifically for SPS, it is not entirely without potential competitors in the development pipeline. Kedrion, for instance, is also working towards a therapy, with its asset Qivigy (immune globulin intravenous human 10% solution) having recently secured FDA orphan drug designation. Qivigy is currently in a Phase III clinical study (NCT07552987) for SPS. Immune globulin treatments work by providing antibodies that can help modulate the immune system. While a different modality, Kedrion’s progress indicates a nascent competitive environment, though miv-cel’s CAR-T mechanism represents a more targeted, potentially curative approach compared to broad immunosuppression. Kyverna’s first-mover advantage and the deep, sustained response observed with miv-cel could set a high bar for future entrants.
Economic Impact and Market Potential:
The market potential for miv-cel, especially if approved for both SPS and gMG, is substantial. While SPS is rare, the high cost associated with advanced therapies for unmet needs, coupled with the potential for premium pricing, could make it a significant revenue generator. The gMG market, already projected to reach $13 billion by 2034, offers an even larger commercial opportunity. Kyverna’s entry into these markets could lead to considerable economic returns, fueling further research and development.
Future Research and Development:
While the one-year data is highly encouraging, ongoing long-term follow-up will be crucial to monitor the durability of response and any potential late-onset adverse events. Further studies may also explore optimal dosing, patient selection criteria, and the potential for miv-cel in other severe autoimmune disorders. The scientific community will be keen to understand the precise mechanisms underlying the observed clinical benefits and how to potentially extend this success to other challenging diseases.
In conclusion, Kyverna Therapeutics’ miv-cel represents a monumental step forward in the treatment of Stiff-Person Syndrome and potentially generalized myasthenia gravis. The sustained one-year efficacy and favorable safety profile position it as a groundbreaking therapy that could fundamentally alter the lives of patients suffering from these debilitating autoimmune conditions. As Kyverna prepares its BLA submission, the medical community and patient advocates alike await with anticipation the potential approval of what could be the first disease-modifying treatment for SPS, heralding a new era of hope and advanced therapeutic options.
